Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2006, p. 4063-4073, Vol. 26, No. 11
0270-7306/06/$08.00+0 doi:10.1128/MCB.01589-05
Copyright © 2006, American
Society for
Microbiology. All Rights Reserved.
Departments of Internal Medicine and Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan 48109,1 Research Division, Joslin Diabetes Center, Boston, Massachusetts 022152
Received 17 August 2005/ Returned for modification 20 September 2005/ Accepted 8 March 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The Jak kinase family contains four members: Jak1 to Jak3 and Tyk2 (11, 16). Of these, Jak1 and -2 and Tyk2 are ubiquitously expressed, while Jak3 is found predominantly in immune and hematopoietic tissues. Jak kinases are composed of four conserved domains. The NH2-terminal FERM domain is required for interaction with cytokine receptors (32, 35), while the adjacent SH2-like fold has no known function. The COOH-terminal portion of Jak kinases contains a kinase-like JH2 domain that is devoid of enzymatic activity but that regulates the activity of the COOH-terminal JH1 tyrosine kinase domain (9, 21, 28, 33, 34).
Our laboratory studies signaling by the long form of the leptin receptor (LRb), which regulates feeding, neuroendocrine, and immune function in response to leptin, which is in turn regulated by nutritional cues (8, 10, 23, 31). Stimulation of LRb mediates the activation and tyrosine phosphorylation of the LRb-associated Jak2, resulting in the phosphorylation of tyrosine residues on the intracellular tail of LRb and on Jak2 (2, 17, 23). Tyrosine phosphorylation sites on LRb mediate signaling by STAT proteins and SHP-2, as well as binding the suppressor of cytokine signaling 3 (SOCS3) to attenuate LRb signaling (2, 3, 23). Several sites of Jak2 tyrosine phosphorylation have been identified, and functions for a few of these sites are known: phosphorylation of Tyr1007 and Tyr1008 within the kinase domain participates in kinase activation (7), phosphorylated Tyr813 mediates binding of SH2-B to increase Jak2 signaling (19), and phosphorylation of Tyr570 within the JH2 domain inhibits Jak2 kinase activity (1, 6).
During our continuing analysis of Jak2 by liquid chromatography-tandem mass spectroscopy (LC-MS/MS), we identified the first-described site of serine phosphorylation (Ser523) on Jak2 protein from intact cells. Here, we report that phosphorylation of Ser523 on Jak2 inhibits Jak2-mediated signaling; this and the high-stoichiometry phosphorylation of this site in intact cells suggest an important role for this phosphorylation event in the regulation of cytokine signaling.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Jak2(758)] antiserum has been described
previously (2,
6). Antigen
affinity-purified phosphorylation-state-specific antibodies to
phosphorylated Tyr1007 and Tyr1008
[
Jak2(PY1007,8)] and Tyr570 [
Jak2(PY570)]
have also been described previously
(6). Antisera for
immunoblotting of Jak2 [
Jak2(NT)] were prepared in rabbits by
injection of a keyhole limpet hemocyanin-coupled synthetic peptide
corresponding to the NH2-terminal 12 amino acids of Jak2.
Antibodies recognizing phosphorylated Ser523 of Jak2 were
raised in rabbits by injection of a keyhole limpet hemocyanin-coupled
synthetic 11-amino-acid phosphorylated peptide centered on
Ser523. All site- and phosphospecific antisera were affinity
purified on the antigen peptide coupled to a mixture of Affigel-10 and
-15 (Bio-Rad), followed by passage over Affigel coupled to irrelevant
phosphopeptides and nonphosphorylated antigen peptide to remove
antibodies directed against other sites of phosphorylation and to the
nonphosphorylated form of the site. The independent preparation of
Jak2(PS523) by the Carter-Su laboratory is described in
reference 21a. Synthetic
peptides were purchased from Boston Biomolecules (Woburn, MA).
9-Fluorenylmethoxy carbonyl-[13C, 15N]-Ile was
purchased from Cambridge Isotope Laboratories (Cambridge, MA) for the
synthesis of mass-labeled peptides by Boston Biomolecules. Recombinant
murine interleukin-3 (IL-3) was obtained from Pierce Endogen (Rockford,
IL); monoclonal 4G10 was used for antiphosphotyrosine (
PY)
immunoblotting (Upstate Biotechnology). Antibodies directed against the
phosphorylated (activated) forms of extracellular signal-regulated
kinase (ERK) and STAT3(PY705) were purchased from Cell Signaling
Technology (Beverly, MA). Recombinant human Epo was purchased from
Amgen. Bovine serum albumin fraction V was purchased from
Sigma. Protein A-Sepharose 6MB and horseradish peroxidase-protein A
were from Amersham Pharmacia Biotech (Piscataway, NJ), and secondary
antibodies for immunoblotting were from Santa Cruz Biotechnology (Santa
Cruz, CA). Dimethylpimelimidate was from Pierce Endogen (Rockford,
IL). Generation of mutant Jak2 cDNAs. pcDNA3Jak2 (17) and pcDNA3Jak2Y570F (6) were used as templates for mutagenesis using the QuickChange kit (Stratagene) to replace Ser523 with Ala or Glu individually (to generate pcDNA3Jak2S523A and pcDNA3Jak2S523E, respectively) or in combination with replacement of Tyr570 by Phe (pcDNA3Jak2S523A/Y570F). The presence of the desired mutations and the absence of adventitious mutations were confirmed by DNA sequencing. Other Jak2 mutants have been described previously (6).
Cell lines. All cells were maintained in a humidified atmosphere containing 5% CO2 and 95% air at 37°C. 32D cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and 5% WEHI-3 conditioned medium (a source of IL-3) (2). HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. ELR constructs in pcDNA3 were transiently cotransfected with pcDNA3 alone or with the appropriate pcDNA3Jak2 isoform into subconfluent HEK293 cells using Lipofectamine (Invitrogen) as described previously (6).
Preparation of cell lysates for immunoprecipitation.
Prior to each experiment,
subconfluent cells plated in 15-cm dishes were made quiescent by
incubation in Dulbecco's modified Eagle's medium containing 0.5% bovine
serum albumin (32D cells, 4 h; 293 cells, overnight) before
stimulation with Epo or IL-3 at 37°C. Cells were lysed in 20 mM
Tris, pH 7.4, containing 137 mM NaCl, 2 mM EDTA, 10% glycerol, 50 mM
ß-glycerophosphate, 50 mM NaF, 1% Nonidet P-40, 2 mM
phenylmethylsulfonyl fluoride, and 2 mM sodium orthovanadate (lysis
buffer). Insoluble material was removed by centrifugation at 16,000
x g at 4°C for 20
min. Protein concentrations of the resulting lysates
were determined using the bicinchoninic acid
protein assay kit (Pierce) and bovine serum albumin
standards, and equivalent amounts of protein were added to
the appropriate antibodies for immunoprecipitation or denatured in
Laemmli buffer for direct resolution by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). For
immunoprecipitates, lysates were incubated with antibody at 4°C
overnight followed by incubation with protein A-Sepharose for 60 min.
All Jak2 immunoprecipitations were performed with
Jak2(758).
Immune complexes were collected by centrifugation and washed
three times in lysis buffer before denaturation in Laemmli
buffer and separation by 8% SDS-PAGE. Immunoblotting was
performed as previously described
(6). Quantification of
immunoblots was accomplished by scanning densitometry of film using
QuantityOne software (Bio-Rad).
For stripping blots, the membrane was stripped with Re-blot Plus (Chemicon) according to the manufacturer's instructions. Stripped membranes were blocked overnight in block buffer and reprobed as described elsewhere.
Analysis of
Jak2 from spleen was accomplished by lysing freshly isolated spleen in
a Dounce homogenizer; lysates were clarified and protein concentration
determined as above. Lysates containing 4.5 mg of protein
each were immunoprecipitated with affinity-purified
Jak2(758) covalently coupled to protein A-Sepharose by the
dimethylpimelimidate method
(24). Immunoblotting of
control immunoprecipitates (no tissue lysate) using this coupled
antibody revealed no reactivity with either
Jak2(PS523) or
Jak2(NT) (data not shown). Mice were C57BL/6 wild-type and
obese, leptin-deficient ob/ob mice from our in-house breeding
program at the University of Michigan. Mice had ad libitum access to
food and water, and all experimental procedures were approved by the
University Committee on the Use and Care of
Animals.
Analysis of SOCS3 mRNA expression.
HEK293 cells
were transfected in triplicate with the ELR and the appropriate Jak2
constructs and made quiescent overnight before stimulation with vehicle
or various concentrations of Epo for an additional 2 h. Cells
were lysed and RNA purified using Trizol reagent (Invitrogen). RNA was
subjected to reverse transcription with the Superscript first-strand
synthesis system (Invitrogen) and subjected to quantitative PCR
analysis for SOCS3 and glyceraldehyde-3-phosphate dehydrogenase using
6-carboxytetramethylrhodamine probes and primers from Applied
Biosystems. Relative amounts of SOCS3 RNA were determined by the
2
Ct method
(20).
Analysis of STAT3 reporter activity. HEK293 cells were transfected in triplicate with the ELR and the appropriate Jak2 constructs plus STAT3-responsive gamma interferon activated sequence (GAS)-Luc and control Renilla luciferase plasmids and made quiescent overnight before stimulation with vehicle or various concentrations of Epo for an additional 12 h. Cells were lysed and assayed for firefly and Renilla luciferase using the dual-luciferase reporter assay system (Promega) on a Victor3 instrument (Perkin-Elmer). Firefly luciferase activity was normalized to Renilla luciferase activity and plotted.
LC-MS/MS analysis.
For preparation of protein for
LC-MS/MS analysis, material was immunoprecipitated from 5 to 10 15-cm
dishes of HEK293 cells and resolved on a single lane of a 7%
SDS-polyacrylamide gel. Jak2 protein was visualized by staining with
Coomassie brilliant blue G-250 (Bio-Rad) and destaining overnight in
10% methanol, 10% glacial acetic acid. Gel slices containing Jak2 were
digested with 5 ng/µl sequencing-grade modified trypsin
(Promega) in 25 mM ammonium bicarbonate containing 0.01%
n-octylglucoside for 18 h at 37°C. Peptides
were eluted from the gel slices with 80% acetonitrile, 1% formic acid.
Tryptic digests were separated by capillary high-pressure liquid
chromatography (C18, 75-µm-inside-diameter Picofrit
column; New Objective) using a flow rate of 100 nl/min over
a 3-h reverse-phase gradient and analyzed using an
LTQ two-dimensional linear ion trap mass
spectrometer (ThermoFinnigan). Resultant MS/MS spectra were matched
against mouse Jak2 sequence using TurboSequest (BioWorks 3.1) with a
fragment ion tolerance of <0.5 and amino acid modification
variables including phosphorylation (80 Da) of Ser, Thr, and
Tyr; oxidation (16 Da) of Met; and methylation (14 Da) of
Lys. Synthetic phosphopeptides, corresponding to tryptic
sequences derived from Jak2, were obtained (Boston Biomolecules, Inc.)
and analyzed using the LC-MS/MS protocol described above. MS/MS spectra
from these synthetic peptide controls and Jak2-derived tryptic peptides
were compared for correlation of fragmentation ion m/z and
abundance. Peptides were quantified using peak areas generated by
liquid chromatography-selective reaction monitoring (LC-SRM;
2+ precursor ion
1+
fragment ion) for Jak2-derived tryptic peptides
TNGISDVQIS(p)PTLQR (854.9
928.5 m/z) and HDFVHGWIK (570.31
886.5 m/z) using internal standards
TNGISDVQ(13C/15N-I)S(p)PTLQR(858.7
935.5 m/z) and
HDFVHGW(13C/15N-I)K (573.47
893.6 m/z). Mass spectroscopic analysis was
performed using a sequence of MS (370 to 2,000 m/z) and
data-dependent MS2 followed by the four SRM events described
above. Precursor and fragment ion isolation widths were 2 and 3
m/z, respectively.
Phosphatase treatment.
Washed
immunoprecipitated protein complexes immobilized on protein A-Sepharose
were prepared as described above, washed three times in the absence of
phosphatase inhibitors, and either resuspended in sample buffer
immediately or resuspended in phosphatase buffer in the absence or
presence of 200 U of
-phosphatase (New England Biolabs) and
incubated for 30 min at 30°C before denaturation in sample
buffer. Samples were resolved by SDS-PAGE and analyzed by
immunoblotting as described
above.
| RESULTS |
|---|
|
|
|---|
Jak2 immunoprecipitation from HEK293 cells transfected with
Jak2 and an Epo receptor/LRb chimera (ELR) that places the
intracellular domain of LRb under the control of Epo. We employ this
chimeric receptor in place of native LRb since ELR is expressed at much
higher levels, thus facilitating the study of signaling by the
intracellular domain of LRb in transfected cells
(2). Jak2 protein purified
by immunoprecipitation from cells that had been incubated in the
absence or presence of Epo for 15 min was resolved by SDS-PAGE and
visualized by staining with Coomassie brilliant blue (data not shown).
This Jak2 protein was subjected to tryptic proteolysis and extracted
from the gel, and the resulting peptides were subjected to LC-MS/MS
analysis. TurboSequest analysis of MS/MS spectra from Jak2-derived
material identified a predicted Jak2 tryptic peptide containing
phosphoserine, TNGISDVQIS(p)PTLQR, with Xcorr
scores of >3.0 for 2+ charged precursor
(Fig.
1, top panel). The spectra displayed ions consistent with the neutral ion
loss of 49 m/z resulting from the loss of HPO3 from
doubly charged phosphoserine-containing peptides. MS/MS spectra
corresponding to peptides containing phosphorylated Ser523
from Jak2 were detected from numerous independent analyses from both
stimulated and unstimulated cells, suggesting that this residue
represents a major site of phosphorylation in intact cells. In order to
confirm the assignment of this phosphorylation site, phosphopeptides
corresponding to the candidate tryptic Jak2 peptide containing
phosphorylated Ser523 and the closest potential alternative
phosphorylation site (Thr525) were synthesized and subjected
to LC-MS/MS analysis (Fig.
1, middle and lower
panels). The appearance and relative abundance of the y4 ion at 614.1
m/z and the neutral loss ion at 49 m/z
correlated with the synthetic peptide containing phosphorylated
Ser523, but not the peptide containing phosphorylated
Thr525, confirming the identification of Jak2
phosphorylation at Ser523.
|
Jak2(PS523)]. We initially tested this antibody for
phosphorylation-dependent recognition of Jak2 by examining reactivity
with exogenously expressed Jak2 from 293 cells and the effect of
dephosphorylation on this recognition (Fig.
2A). Cells
were transfected with ELR and Jak2, made quiescent, and
incubated in the absence or presence of Epo for 15 min before
immunoprecipitation. Cells were lysed, and Jak2 was immunoprecipitated;
washed immunoprecipitates were then either directly denatured or
incubated in the presence or absence of alkaline phosphatase before
denaturation. Denatured proteins were resolved by SDS-PAGE for
immunoblotting with
PY,
Jak2(PS523), or
Jak2(NT), as indicated. The
Jak2(NT) immunoblots
demonstrated that, while some Jak2 protein was lost during the
incubation, the presence of the phosphatase during the incubation did
not alter the amount of protein retained. Immunoblotting with
PY demonstrated the tyrosine phosphorylation of Jak2 and
confirmed the expected increase in Jak2 tyrosine phosphorylation upon
ligand stimulation. Incubation of the immunoprecipitated Jak2 with
alkaline phosphatase almost entirely abrogated the
PY
reactivity of Jak2, suggesting that this treatment effectively
dephosphorylated Jak2. Immunoblotting with
Jak2(PS523)
revealed similar levels of immunoreactivity in the absence and in the
presence of Epo stimulation and showed that phosphatase treatment
abrogated immunoreactivity, demonstrating the phosphospecificity of
Jak2(PS523) reactivity. Stripping of the
Jak2(NT)
membrane and reprobing with
Jak2(PS523)(CS)
antiserum provided by the Carter-Su laboratory (see reference
21a) demonstrated
similar phosphospecificity of this antiserum, as well.
|
Jak2(PS523) and to probe
the potential function of Ser523 phosphorylation, we also
generated a phosphorylation site-defective mutant of Jak2 in which
Ser523 was replaced by Ala (Jak2S523A). We
transfected HEK293 cells with ELR in combination with control plasmid
or plasmids encoding Jak2 or Jak2S523A (Fig.
2B). Cells were incubated
in the absence or presence of Epo and lysed, and lysates were
immunoprecipitated with
Jak2(758) or directly resolved for the
determination of downstream ELR signaling.
Jak2(PS523)
immunoblotting of
Jak2-precipitable material again
demonstrated ligand-independent immunoreactivity; this reactivity was
absent in Jak2S523A. Similar results were obtained with
Jak2(PS523) prepared independently by the Carter-Su
laboratory. Thus,
Jak2(PS523) reactivity is specific for
phosphorylation of Ser523; these data also suggest either
that the basal phosphorylation of Ser523 in HEK293 cells is
very high or that brief stimulation of Jak2 activity is insufficient to
increase the phosphorylation of this site.
The
analysis of
PY immunoreactivity again demonstrated the
expected ligand-stimulated tyrosine phosphorylation of Jak2; the
tyrosine phosphorylation of Jak2S523A was increased compared
to that of wild-type Jak2 in the absence of ligand stimulation and only
slightly increased over this high baseline level upon Epo treatment
(Fig. 2B). In order to
examine whether the increased overall tyrosine phosphorylation of
Jak2S523A was likely to reflect increased activation of
Jak2S523A, we performed immunoblot analysis of Jak2 and
Jak2S523A using
Jak2(PY1007,8), which detects the
phosphorylation of the activation loop within the kinase domain of Jak2
and thus reflects the activation of the Jak2 tyrosine kinase. This
analysis demonstrated increased phosphorylation of Tyr1007,8
on Jak2S523A compared to Jak2 in the basal state as well as
the expected Epo-stimulated increase in phosphorylation.
Overexpression of Jak2 with ELR also increased the ligand-dependent and
-independent phosphorylation of the downstream STAT3 and ERK molecules
compared to the levels observed in cells expressing ELR alone (which
mediated some activation of these signals via endogenous Jak2 in the
absence of overexpressed Jak2 isoforms). The presence of
Jak2S523A increased the phosphorylation of these molecules
compared to that observed with Jak2. While quantification demonstrated
that the increase in these downstream signaling events in cells
expressing Jak2S523A was not statistically significant
compared to cells expressing Jak2 (perhaps due to the maximal amplitude
of these signals in cells expressing Jak2), the increase in basal
activity was increased by two- to threefold (P < 0.05)
by Jak2S523A compared to Jak2 (Fig.
2C to
F).
Furthermore, the expression of endogenous SOCS3 mRNA (a reflection of ELR-mediated STAT3 activation [27]) was similarly increased in unliganded cells expressing Jak2S523A compared to those expressing Jak2 (P < 0.05). Again, the failure to detect increased signaling following ligand stimulation may reflect the maximal nature of the signal generated by overexpressed Jak2 in the presence of ligand especially at short times of incubation (see below and Fig. 6D). In aggregate, these data demonstrated that mutation of Ser523 increased the tyrosine phosphorylation and activity of Jak2, suggesting that the phosphorylation of Ser523 may inhibit Jak2.
|
Jak2(758) or directly
resolved by SDS-PAGE (Fig.
3). Immunoprecipitated Jak2 protein was immunoblotted with
PY,
Jak2(PS523), and
Jak2(NT), and total lysates were
probed with
STAT3(PY) and
ERK(PT/PY). As expected,
IL-3 stimulation resulted in increased phosphorylation of Jak2, STAT3,
and ERK, consistent with the known effects of IL-3 in these cells.
Immunoblotting of
Jak2(758) immunoprecipitates with
Jak2(PS523) demonstrated the phosphorylation of endogenous
Jak2 on Ser523 in these cells in the absence or presence of
IL-3 stimulation. Thus, Ser523 of Jak2 is phosphorylated in
multiple cell types, and the regulation of Ser523
phosphorylation is not affected by acute leptin or IL-3 stimulation in
HEK293 or 32D cells, respectively.
|
Jak2(PS523) demonstrated that this residue was phosphorylated
in mouse tissue, although its phosphorylation was not detectably
altered by leptin deficiency or obesity in obese, leptin-deficient
ob/ob mice. Thus, Ser523 is phosphorylated on
endogenous Jak2 in cultured cells and tissues. The failure of absent
leptin action to appreciably alter phosphorylation of this site in
spleen suggests that the phosphorylation of Ser523 of Jak2
is regulated by signaling pathways whose activity converges upon the
Jak2 pathway, at least in this
tissue.
Replacement of Ser523 by Glu activates Jak2 in HEK293 cells.
Replacement of amino acids with acidic
side chains for Ser or Thr phosphorylation sites on enzymes (such as
kinases) often modestly mimics phosphorylation
(4). We therefore replaced
Ser523 with Glu on Jak2 (Jak2S523E) in order to
determine whether this mutation might mimic phosphorylation of
Ser523. We transfected HEK293 cells with ELR plus control
plasmid, Jak2, or Jak2S523E and rendered the cells quiescent
before incubating them in the absence or presence of Epo
for 15 min and lysing them. Lysates were directly
resolved by SDS-PAGE for immunoblotting with
STAT3(PY) and
ERK(PT/PY) or immunoprecipitated with
Jak2(758) for immunoblotting with
PY,
JAK2(PS523), and
Jak2(NT) (Fig.
4). We found that basal Jak2S523E tyrosine phosphorylation was
increased compared to that of Jak2, although the Epo-stimulated
tyrosine phosphorylation of Jak2S523E was similar to that of
wild-type Jak2. Quantification of tyrosine-phosphorylated Jak2 relative
to Jak2 expression for two independent experiments demonstrated an
approximately twofold increase in the basal tyrosine phosphorylation of
Jak2S523E for each experiment (data not shown); the tyrosine
phosphorylation of ligand-stimulated Jak2S523E was also
modestly increased compared to Jak2 in each experiment. Furthermore,
the basal phosphorylation of STAT3 and that of ERK were also increased
in cells expressing Jak2S523E compared to cells expressing
Jak2 in each experiment (data not shown). These data suggest that the
substitution of Glu for Ser523 results in an
activated/disinhibited phenotype similar to that for the substitution
of Ala for Ser523, at least in the unstimulated
state.
|
High-stoichiometry phosphorylation of Ser523 in HEK293 cells. We thus employed LC-SRM using mass-tagged synthetic peptide standards (13) in order to examine the stoichiometry of Ser523 phosphorylation on Jak2 from HEK293 cells. Jak2 was isolated from unstimulated and Epo-stimulated HEK293 cells, as described for Fig. 1 (Fig. 5A). Six picomoles of TNGISDVQ(13C/15N-I)S(p)PTLQRand HDFVHGW(13C/15N-I)Kwere added to both Jak2 tryptic digests, and LC-SRM was performed as described in Materials and Methods. The mass-tagged peptides and corresponding Jak2-derived peptides eluted with identical retention times (Fig. 5B). Area under the curve was calculated for the SRM peak, and peptide amounts were calculated from standard curves of mass-tagged peptides. The concentration of HDFVHGWIK was used to estimate the amount of total Jak2 present and compared with the amount of TNGISDVQIS(p)PTLQR in each sample. Multiple LC-SRM experiments revealed that approximately 80 to 95% of Jak2 molecules from HEK293 cells are phosphorylated on Ser523 under the conditions employed for this analysis, with no detectable difference between stimulated and unstimulated HEK293 cells (Fig. 5B). The completeness of Ser523 phosphorylation in cultured cells suggests its importance in the regulation of Jak2 function.
|
Jak2(758) for immunoblotting with
PY,
Jak2(PS523), and
Jak2(NT) or directly
resolved by SDS-PAGE for immunoblotting with
STAT3(PY) and
ERK(PT/PY). As expected, the tyrosine phosphorylation of Jak2
and the phosphorylation of STAT3 and ERK were increased in cells
expressing Jak2S523A compared to cells expressing Jak2,
while the tyrosine phosphorylation of Jak2Y1007F was
undetectable. The phosphorylation of STAT3 and ERK in cells expressing
Jak2Y1007F was also decreased compared to cells expressing
Jak2 (the remaining signaling was presumably due to the activity of
endogenous Jak2 in HEK293 cells, as seen in Fig.
2 and
4, above). The
phosphorylation of Ser523 in Jak2Y1007F was
detected at similar levels both in the absence and in the presence of
ligand stimulation and at levels comparable to those observed in Jak2.
These data suggest that the kinase activity of Jak2 is not required for
the phosphorylation of Ser523 in HEK293 cells and that
converging signaling pathways that can be activated independently of
Jak2 are thus responsible for the phosphorylation of Ser523
in these cells.
Additive functions of Ser523 and Tyr570 in the regulation of Jak2 activity.
We and others have
previously demonstrated that the phosphorylation of Tyr570
on Jak2 inhibits Jak2-dependent signaling
(1,
6). Given the relative
proximity and similar functions of Ser523 and
Tyr570, we generated a Jak2 molecule containing
nonphosphorylatable amino acid substitutions at each of these sites
(Jak2S523A/Y570F) in order to examine the possibility of
interaction between these two sites (Fig.
6B to D).
HEK293 cells transfected with ELR alone or in combination with Jak2,
Jak2S523A, Jak2Y570F, or
Jak2S523A/Y570F were made quiescent overnight, incubated in
the absence or presence of Epo for 15 min, and lysed. In this case, we
decreased the amount of Jak2 isoform DNA that was transfected in each
case by a factor of 3.3 compared to that used in preceding figures in
order to decrease the amplitude of the effects of the mutations and
thus permit the more facile determination of differences between these
Jak2 isoforms. Lysates were immunoprecipitated with
Jak2(758) for immunoblotting with
Jak2(PY1007,8),
Jak2(PS523), and
Jak2(NT) (Fig.
6B). The baseline
activation of each of the single point mutants was increased compared
to Jak2, as judged by the activation-loop-specific tyrosine
phosphorylation; the phosphorylation of the double
Jak2S523A/Y570F mutant was increased beyond that observed
with the single point mutants (quantification of phosphorylation
normalized to Jak2 protein levels in two independent experiments is
shown in Fig. 6C). As
expected, phosphorylation of Ser523 was absent in
Jak2S523A and Jak2S523A/Y570F, and
phosphorylation of Tyr570 was absent in
Jak2Y570F and Jak2S523A/Y570F.
In order to quantitatively examine the ligand sensitivity of these mutants, we cotransfected them with ELR plus a STAT3-responsive GAS-luciferase reporter plasmid and examined the effect of these Jak2 mutants on STAT3-mediated transcription in response to various submaximal doses of Epo (Fig. 6D). This analysis demonstrated that each Jak2 mutant mediated increased STAT3-mediated transcription compared to wild-type Jak2 at each dose of ligand tested (P < 0.001) and demonstrated that the double mutant mediated increased reporter activity compared to the single mutants at baseline and the lowest dose of Epo (0.1 units/ml) tested (P < 0.05). Overall, these data demonstrate independent and additive effects of Ser523 and Tyr570 in the inhibition of Jak2 activity, as well as demonstrating increased ligand sensitivity of Jak2 molecules defective for phosphorylation of either or both of these sites.
Increased and prolonged signaling by Jak2S523A.
The observed increase in ELR
signaling in the presence of Jak2S523A compared to Jak2,
above, suggested that mutation of the Ser523 phosphorylation
site might increase the amplitude and/or duration of signaling by the
intracellular tail of LRb. We thus examined the possibility that
Ser523 regulates the attenuation of Jak2-dependent signaling
by studying the temporal regulation of Jak2 phosphorylation in HEK293
cells transfected with ELR and control plasmid, Jak2, or
Jak2S523A (Fig.
7). Since the dephosphorylation and attenuation of STAT3
signaling are modest over the first 24 h of stimulation
(5) and since the first
phase of ERK signaling attenuates very rapidly, we did not analyze the
phosphorylation of these proteins in this assay but rather focused upon
the tyrosine phosphorylation of Jak2 and Jak2S523A. Cells
were incubated with maximal amounts (10 units/ml) of Epo for various
times up to 8 h and lysed. Immunoprecipitated Jak2 protein
was resolved by SDS-PAGE and immunoblotted with
PY,
Jak2(PS523), and
Jak2(NT) (Fig.
7A and B). In two
independent experiments, immunoblotting with
PY demonstrated
the expected rapid Epo-stimulated increase in tyrosine phosphorylation
of Jak2 and the expected decrease in tyrosine phosphorylation of Jak2
after approximately 30 min of stimulation, as previously reported
(5,
6). While Epo stimulation
also increased the tyrosine phosphorylation of Jak2S523A,
the tyrosine phosphorylation of Jak2S523A again reached much
higher levels of activation than Jak2 and did not attenuate appreciably
over the 8 h of stimulation. Furthermore, differences in
tyrosine phosphorylation between Jak2 and Jak2S523A were
more pronounced after 30 to 60 min of stimulation, suggesting that the
differences between Jak2 and Jak2S523A at 15 min of
stimulation in the preceding figures underestimate the magnitude in the
differences between these two molecules. In order to facilitate the
comparison of signal activation and attenuation between Jak2 and
Jak2S523A, we quantified and graphed the tyrosine
phosphorylation of each Jak2 isoform relative to Jak2 expression for
each of these molecules in the experiments shown (Fig.
7C), demonstrating the
increased duration of signaling in cells expressing
Jak2S523A following a maximal stimulus. These data suggest
that Ser523 is required for the normal attenuation of Jak2
phosphorylation following ligand stimulation. Interestingly, in each of
these experiments, in which the transfected HEK293 cells were serum
deprived for longer than in the preceding experiments, some increased
phosphorylation of Ser523 on Jak2 was detected at brief
times of stimulation. This result is consistent with the idea that high
baseline activation of a variety of signaling pathways in HEK293 cells
may result in high baseline phosphorylation of
Ser523 but that increased times of serum starvation may
decrease this activity to yield somewhat lower stoichiometry of
Ser523 phosphorylation at baseline, such that activation of
ELR-Jak2 signaling results in increased Ser523
phosphorylation.
|
| DISCUSSION |
|---|
|
|
|---|
Overall, our data suggest that the phosphorylation of Ser523 inhibits Jak2 signaling. This is consistent with the known effects of serine phosphorylation in the inhibition of a variety of other tyrosine kinases and their downstream signaling pathways and previous reports suggesting an inhibitory effect of increased overall Ser/Thr phosphorylation on Jak2 (12, 18, 26, 29, 30). While the exact mechanism of this inhibition is not clear, the findings of increased basal activity and increased duration of signaling during cytokine receptor activation in Jak2S523A suggest that phosphorylation of Ser523 may act to inhibit the enzymatic activity of the Jak2 tyrosine kinase, rather than altering the transmission of the activating signal from the ligand/receptor complex to the associated Jak2 molecule.
Ser523 is not conserved among other Jak kinase family members. Thus, this regulatory phosphorylation event is likely to be unique to Jak2. This residue lies within a stretch of approximately 15 amino acids within the region between the SH2-like domain and JH2 domains of Jak2 and is poorly conserved in other Jak kinases. In one predicted model of the overall structure of Jak2 (14), this region forms a loop that directly overlies the interface between the SH2-like and JH2 domains, and this loop projects Ser523 directly toward a closely apposed tyrosine kinase domain. Thus, phosphorylated Ser523 could theoretically regulate the activity of the Jak2 tyrosine kinase by modifying the overall conformation of the JH2/SH2-like domain interface and thus the tertiary structure of Jak2, or it could directly impinge upon the kinase domain to regulate its activity.
Given the proximity of Ser523 to the JH2 domain and the previously reported role for the JH2 tyrosine phosphorylation site (Tyr570) in inhibiting Jak2 activity, we explored the possibility that these sites might operate in an interdependent manner. This analysis demonstrated that the phosphorylation of Ser523 was independent of Tyr570 and that mutation of Ser523 further activated a Jak2 molecule with a substitution mutation at Tyr570, demonstrating that the effect of Ser523 is independent of Tyr570 and suggesting that the phosphorylation of each site represents an independent mechanism for Jak2 inhibition. This independence of Ser523- and Tyr570-mediated inhibition of Jak2 activity is consistent with the likely requirement for the regulation of Jak2 activity by numerous pathways within a given cell and is also consistent with the different mechanisms by which these two sites are regulated. Not only is the phosphorylation of these sites mediated via different kinases (Tyr570 by Jak2-mediated autophosphorylation and Ser523 by an unknown serine kinase), but the phosphorylation of Ser523 is also apparently high in unstimulated cells and not dependent upon the activity of Jak2 in HEK293 cells.
We have found it difficult to detect regulation of Ser523 phosphorylation in HEK293 or 32D cells. Based upon the finding that mutation of Ser523 to Ala or Glu activates Jak2, we hypothesized that the phosphorylation of Ser523 may be close to stoichiometric in unstimulated HEK293 cells under our usual conditions. Under these conditions, the presence of Glu in place of Ser523 might be expected to inhibit Jak2 to some extent compared to the Ala mutant but would inhibit much less well than the presence of phosphorylated Ser523 on virtually every Jak2 molecule. Furthermore, high levels of Ser523 phosphorylation in unstimulated cells would render it difficult to stimulate further phosphorylation of the residue. Indeed, our LC-SRM analysis with mass-labeled peptide standards demonstrated that the stoichiometry of Ser523 phosphorylation approached unity in unstimulated and Epo-stimulated HEK293 cells expressing exogenous ELR and Jak2. The finding of phosphorylated Ser523 on endogenous Jak2 from 32D cells and mouse spleen coupled with the observed high stoichiometry of Ser523 phosphorylation in HEK293 cells suggests the potential physiologic importance of Ser523 phosphorylation in the regulation of Jak2 function. Furthermore, the finding that neither leptin (in spleen) nor Jak2 activity (in transfected HEK293 cells) is required for the phosphorylation of Ser523 suggests the importance of converging signaling pathways for the regulation of LRb-Jak2 signaling by this phosphorylation event.
Furthermore, while a Pro lies directly COOH
terminal to Ser523, 30 to 60 min of inhibition of
Pro-directed Ser/Thr kinases (e.g., ERK) in HEK293 cells failed to
alter the phosphorylation of Ser523 (see Fig. S1 in the
supplemental material). It is important to note that in the presence of
very high baseline phosphorylation of Ser523, however, the
failure of this inhibitor to block phosphorylation could
reflect a low rate of dephosphorylation, rather than the irrelevance of
these kinases. Indeed, the Carter-Su laboratory, which independently
identified and studied the phosphorylation of Ser523,
describes in reference
21a the MEK-dependent
regulation of Ser523 phosphorylation by growth hormone in
3T3-F442A preadipocytes. We do not attribute this discrepancy in our
findings to differences in antibody preparation, as we have used a
highly purified antibody (see Materials and Methods) and have
recapitulated our results from HEK293 cells with
Jak2(PS523)
antisera provided by the Carter-Su laboratory (Fig.
2). Rather, we
hypothesize that the observed differences in the regulation of
Ser523 phosphorylation reflect differences in cell systems,
in which 3T3-F442A cells are more fully quiescent than HEK293 cells
(which contain high levels of tyrosine-phosphorylated IRS-4 even
following prolonged starvation) or 32D cells (which can be deprived of
growth factor for only a few hours prior to study lest they become
apoptotic), such that the endogenous Jak2 protein from 3T3-F442A cells
may contain significantly less phosphorylated Ser523 on a
per-mole basis than that from HEK293 or 32D cells. Indeed, not only is
the phosphorylation of Ser523 detectable at baseline in
3T3-F442A cells but prolonged serum starvation of HEK293 cells appears
to lower baseline phosphorylation of Ser523, enabling the
detection of regulation of Ser523 phosphorylation during
signaling by the intracellular domain of LRb. Thus, in aggregate, the
phosphorylation of Ser523 can likely function to
mediate feedback inhibition of Jak2 activity during cytokine
stimulation as well as inhibiting Jak2 signaling downstream of other,
Jak2-independent, pathways within the cell.
While determining the exact mechanism by which phosphorylation of Ser523 inhibits Jak2 signaling will require further study, it is clear that the phosphorylation of this site represents an important mechanism by which Jak2-dependent signaling is regulated. Enhancing the phosphorylation of Ser523 would necessarily decrease the strength of Jak2-dependent signals and could underlie impaired signaling by Jak2-dependent cytokines, such as leptin in the leptin resistance that accompanies common forms of obesity (8, 10, 22). On the other hand, impairment of Ser523 phosphorylation or Ser523-mediated inhibition would be expected to increase cytokine action, as in autoimmunity or tumor promotion (25). Further investigation will be required to determine the role of Jak2 inhibition via Ser523 phosphorylation in these and other disease processes.
| ACKNOWLEDGMENTS |
|---|
We are grateful to Diane Fingar for a critical
reading of the manuscript. Thanks go to the laboratory of Christin
Carter-Su for sharing their preparation of
Jak2(PS523).
| FOOTNOTES |
|---|
Supplemental material for this article may be found at
http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Banks, A. S., S. M. Davis, S. H. Bates, and
M. G. Myers, Jr. 2000. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem.
275:14563-14572.
3. Bjorbaek,
C., H. J. Lavery, S. H. Bates, R. K. Olson, S. M. Davis, J. S. Flier, and M.
G. Myers, Jr. 2000. SOCS3 mediates feedback inhibition
of the leptin receptor via Tyr985. J. Biol.
Chem. 275:40649-40657.
4. Dennis, P. B., N. Pullen, S. C. Kozma, and G. Thomas.1996 . The principal rapamycin-sensitive p70s6k phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol. Cell. Biol. 16:6242-6251.[Abstract]
5. Dunn,
S. L., M. Bjornholm, S. H. Bates, Z. Chen, M.
Seifert, and M. G. Myers, Jr. 2005. Feedback
inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin
receptor and suppressor of cytokine signaling 3. Mol.
Endocrinol.
19:925-938.
6. Feener,
E. P., F. Rosario, S. L. Dunn, Z. Stancheva, and
M. G. Myers, Jr. 2004. Tyrosine
phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.Mol. Cell. Biol.
24:4968-4978.
7. Feng, J., B. A. Witthuhn, T. Matsuda, F. Kohlhuber, I. M. Kerr, and J. N. Ihle. 1997. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:2497-2501.[Abstract]
8. Flier, J. S., and E. Maratos-Flier. 1998. Obesity and the hypothalamus: novel peptides for new pathways.Cell 92:437-440.[CrossRef][Medline]
9. Frank,
S. J., W. Yi, Y. Zhao, J. F. Goldsmith, G.
Gilliland, J. Jiang, I. Sakai, and A. S. Kraft.1995
. Regions of the Jak2 tyrosine kinase required for
coupling to the growth hormone receptor. J. Biol.
Chem.
270:14776-14785.
10. Friedman, J. M. 2002. The function of leptin in nutrition, weight, and physiology. Nutr. Rev. 60:S1-S14.[Medline]
11. Gadina, M., D. Hilton, J. A. Johnston, A. Morinobu, A. Lighvani, Y. J. Zhou, R. Visconti, and J. J. O'Shea.2001 . Signaling by type I and II cytokine receptors: ten years after. Curr. Opin. Immunol. 13:363-373.[CrossRef][Medline]
12. Gandino, L., M. F. Di Renzo, S. Giordano, F. Bussolino, and P. M. Comoglio. 1990. Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. Oncogene 5:721-725.[Medline]
13. Gerber,
S. A., J. Rush, O. Stemman, M. W. Kirschner, and
S. P. Gygi. 2003. Absolute quantification of
proteins and phosphoproteins from cell lysates by tandem MS. Proc.Natl. Acad. Sci. USA
100:6940-6945.
14. Giordanetto,
F., and R. T. Kroemer. 2002. Prediction of
the structure of human Janus kinase 2 (JAK2) comprising JAK homology
domains 1 through 7. Protein Eng.
15:727-737.
15. Herrington, J., and C. Carter-Su. 2001. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol. Metab. 12:252-257.[CrossRef][Medline]
16. Ihle,
J. N., W. Thierfelder, S. Teglund, D. Stravapodis, D. Wang,
J. Feng, and E. Parganas. 1998. Signaling by the
cytokine receptor superfamily. Ann. N. Y. Acad.
Sci.
865:1-9.
17. Kloek,
C., A. K. Haq, S. L. Dunn, H. J. Lavery,
A. S. Banks, and M. G. Myers, Jr.2002
. Regulation of Jak kinases by intracellular leptin
receptor sequences. J. Biol. Chem.
277:41547-41555.
18. Kovanen,
P. E., I. Junttila, K. Takaluoma, P. Saharinen, L. Valmu, W.
Li, and O. Silvennoinen. 2000. Regulation of Jak2
tyrosine kinase by protein kinase C during macrophage differentiation
of IL-3-dependent myeloid progenitor cells. Blood
95:1626-1632.
19. Kurzer,
J. H., L. S. Argetsinger, Y.-J. Zhou, J.-L.
Kouadio, J. J. O'Shea, and C. Carter-Su.2004
. Tyrosine 813 is a site of JAK2 autophosphorylation
critical for activation of JAK2 by SH2-Bß. Mol. Cell.
Biol.
24:4557-4570.
20. Livak,
K. J., and T. D. Schmittgen. 2001.
Analysis of relative gene expression data using real-time quantitative
PCR and the 2(
C(T)) method.Methods
25:402-408.[CrossRef][Medline]
21. Luo, H., P. Rose, D. Barber, W. P. Hanratty, S. Lee, T. M. Roberts, A. D. D'Andrea, and C. R. Dearolf.1997 . Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 17:1562-1571.[Abstract]
21. Mazurkiewicz-Munoz,
A. M., L. S. Argetsinger, J.-L. K.
Kouadio, A. Stensballe, O. N. Jensen, J. M. Cline,
and C. Carter-Su. 2006. Phosphorylation of JAK2 at
serine 523: a negative regulator of JAK2 that is stimulated by growth
hormone and epidermal growth factor. Mol. Cell. Biol.
26:4052-4062.
22. Munzberg, H., and M. G. Myers, Jr. 2005. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 8:566-570.[CrossRef][Medline]
23. Myers,
M. G., Jr. 2004. Leptin receptor signaling
and the regulation of mammalian physiology. Recent Prog. Horm.
Res.
59:287-304.
24. Myers,
M. G., Jr., L. M. Wang, X. J. Sun, Y.
Zhang, L. Yenush, J. Schlessinger, J. H. Pierce,
and M. F. White. 1994. The role of
IRS-1/GRB2 complexes in insulin signaling. Mol. Cell.
Biol.
14:3577-3587.
25. O'Shea, J. J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:37-45.[CrossRef][Medline]
26. Rui, L., V. Aguirre, J. K. Kim, G. I. Shulman, A. Lee, A. Corbould, A. Dunaif, and M. F. White.2001 . Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways.J. Clin. Investig. 107:181-189.[CrossRef][Medline]
27. Saatcioglu, F., G. Lopez, B. L. West, E. Zandi, W. Feng, H. Lu, A. Esmaili, J. W. Apriletti, P. J. Kushner, J. D. Baxter, and M. Karin. 1997. Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity. Mol. Cell. Biol. 17:4687-4695.[Abstract]
28. Saharinen,
P., and O. Silvennoinen. 2002. The pseudokinase domain
is required for suppression of basal activity of Jak2 and Jak3 tyrosine
kinases and for cytokine-inducible activation of signal transduction.J. Biol. Chem.
277:47954-47963.
29. Takayama,
S., M. F. White, and C. R. Kahn.1988
. Phorbol ester-induced serine phosphorylation of the
insulin receptor decreases its tyrosine kinase activity.J. Biol. Chem.
263:3440-3447.
30. Tanti,
J. F., T. Gremeaux, E. Van Obberghen, and Y. Le
Marchand-Brustel. 1994. Serine/threonine
phosphorylation of insulin receptor substrate 1 modulates insulin
receptor signaling. J. Biol. Chem.
269:6051-6057.
31. Tartaglia,
L. A. 1997. The leptin receptor.J. Biol. Chem.
272:6093-6096.
32. Velazquez,
L., K. E. Mogensen, G. Barbieri, M. Fellous, G. Uze, and S.
Pellegrini. 1995. Distinct domains of the protein
tyrosine kinase tyk2 required for binding of
interferon-
/ß and for signal transduction.J. Biol. Chem.
270:3327-3334.
33. Yeh,
T. C., E. Dondi, G. Uze, and S. Pellegrini.2000
. A dual role for the kinase-like domain of the
tyrosine kinase Tyk2 in interferon-alpha signaling. Proc. Natl.
Acad. Sci. USA
97:8991-8996.
34. Zhao,
Y., F. Wagner, S. J. Frank, and A. S. Kraft.1995
. The amino-terminal portion of the JAK2 protein
kinase is necessary for binding and phosphorylation of the
granulocyte-macrophage colony-stimulating factor receptor beta c chain.J. Biol. Chem.
270:13814-13818.
35. Zhou, Y. J., M. Chen, N. A. Cusack, L. H. Kimmel, K. S. Magnuson, J. G. Boyd, W. Lin, J. L. Roberts, A. Lengi, R. H. Buckley, R. L. Geahlen, F. Candotti, M. Gadina, P. S. Changelian, and J. J. O'Shea. 2001. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8:959-969.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||